All companies
Repligen logo

What smart money is saying about RepligenUnited States flag

RGEN · Healthcare · Medical - Instruments & Supplies · Market cap $9.51B

3 funds in our archive have pitched Repligen — most recently Granahan Investment Management Focused Growth Strategy in June 2026.

Company profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Get an email when a fund writes about it

Summarize with Warren AI
2
Reported positions
1
Bought
1
Sold
6
Letters

Position history

Between Q4 2025 and Q2 2026, 2 fund letters reported a position in Repligen1 opened or added to the position, 1 trimmed or exited.

Fund letters reporting a position in Repligen, by quarter
QuarterLettersBoughtSoldTheses
Q2 20262111
Q4 20250002

Fund activity · 2 positions · 2 moves

Also mentioned · 2

These funds discuss Repligen — as a competitor, benchmark or comparable — without disclosing a position in it.

Fund coverage · 3 theses

Read every full thesis on Repligen

Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger